Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.
Gastric cancer (GC) ranks as the fifth most common cancer diagnosed worldwide.
APA
Wang Y, Chong G (2025). Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.. Critical reviews in oncology/hematology, 216, 104941. https://doi.org/10.1016/j.critrevonc.2025.104941
MLA
Wang Y, et al.. "Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.." Critical reviews in oncology/hematology, vol. 216, 2025, pp. 104941.
PMID
40953757
Abstract
Gastric cancer (GC) ranks as the fifth most common cancer diagnosed worldwide. Despite advances in treatment, the prognosis for patients remains poor. Immune checkpoint inhibitors have been increasingly utilised across all settings in the treatment of GC and gastroesophageal junction (GEJ) adenocarcinomas; from perioperative treatment of resectable early-stage G/GEJ cancers to combination with chemotherapy and targeted agents in metastatic disease. This review aims to summarise the molecular subtypes of GC, outline the key evidence for the use of immunotherapy in early and advanced stage settings and discuss biomarkers and novel immunotherapeutics for GC.
MeSH Terms
Humans; Stomach Neoplasms; Adenocarcinoma; Immunotherapy; Immune Checkpoint Inhibitors; Biomarkers, Tumor; Esophagogastric Junction
같은 제1저자의 인용 많은 논문 (5)
- "I wanna look like the person in that picture": Linking selfies on social media to cosmetic surgery consideration based on the tripartite influence model.
- ZmSKIP enhances drought tolerance by reducing stomatal aperture in maize.
- c.7374_7375insAlu is a French-Canadian founder pathogenic variant associated with predisposition to pancreatic and breast cancer.
- Enhancing Node-RADS for preoperative assessment of cervical lymph node metastases in papillary thyroid carcinoma: validation and modification.
- Aging modulation of the immune system and immunotherapy efficacy in cancer.